Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial

Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.

Related Keywords

Dallas ,Texas ,United States ,American ,Baylor Scott ,Javed Butler ,American College Of Cardiology ,Institute Javed Butler ,University Of Mississippi ,American Heart Association ,White Research Institute ,American College ,Annual Scientific Session ,Dont Miss ,Confidence Interval ,After Acute Myocardial Infarction ,Results Of The ,Annual Scientific ,Myocardial Infarction ,Redefining Cardiometabolic ,Show Mixed Results After Heart ,